Jerome H. Kim, M.D., is the Director General of the International Vaccine Institute (IVI). He served as the Principal Deputy and Chief of the Laboratory of Molecular Virology and Pathogenesis at MHRP, in addition to being the Project Manager for the HIV Vaccines and Advanced Concepts Evaluation Project Management Offices, U.S. Army Medical Material Development Activity U.S.A., Dr. Kim was a Professor within the Division of Infectious Diseases of the Department of Medicine at the Uniformed Services University of the Health Sciences. From 2004 – 2009 he led the Army’s Phase III HIV vaccine trial (RV144), the first demonstration that an HIV vaccine could protect against infection, as well as subsequent studies that identified laboratory correlates of protection and sequence changes in breakthrough HIV infections after vaccination. Dr. Kim graduated from the Yale University School of Medicine in 1984 and completed his training in Internal Medicine and fellowship in Infectious Diseases at Duke University Medical Center. In 2013 he received the John Maher Award for Research Excellence from the Department of Medicine, Uniformed Services University of the Health Sciences. Throughout his career to date, Dr. Kim has authored over 200 publications.

Dr. T. Anh Wartel, M.D., is the Associate Director General of IVI’s Epidemiology, Public Health, Impact, Clinical Development unit. She has 20 years of experience in epidemiological studies, clinical research from phase I to phase IV studies, and CTD development. She earned her MD at the Paris XII Medical School, France and completed a post-graduate diploma in Public Health from the University of Liverpool, UK. She has extensive experience in the fields of epidemiological and clinical research within both academia and the pharmaceutical industry during her 15 year-long career with Sanofi Pasteur before joining IVI in 2018. After having started her research career as a co-investigator in drugs and therapeutic vaccine trials in HIV infected patients at the French National Agency of Research on HIV/AIDS (ANRS) at Kremlin Bicetre University Hospital in Paris, she then joined Sanofi Pasteur in 2003. Her responsibilities grew over the course of 15 years to include Epidemiology and Clinical R&D activities (e.g., Japanese encephalitis, Pneumococcal Disease, Dengue Disease); Medical Affairs activities as the Regional Medical Expert for enteric, endemic and travelers vaccines (e.g., rabies, cholera, typhoid fever, hepatitis A, yellow-fever, dengue, Japanese encephalitis vaccines); and Country Medical Head for Vietnam and Cambodia. She joined IVI in September of 2018.

Mr. Francois Belin is the Deputy Director General, Chief Operating Officer of IVI. He is a finance professional with an extensive global pharmaceuticals and cross-cultural background, having served in increasingly senior finance positions over the course of the last 23 years, first in Pfizer, then Sanofi. Within Pfizer he held positions as CFO for Central & Eastern Europe (Karlsruhe), Canada (Montreal), Japan (Tokyo), and Emerging Markets & Asia Regional CFO (New York). Upon joining Sanofi, he served as Group CFO China/Asia in Shanghai, before taking the role of Vice President, Head of Finance Transformation in the Sanofi HQ in Paris until joining IVI. Mr. Belin was born in Germany, lived in Italy, and holds an M.Sc. in Management from ESSEC Business School (France).

Dr. Han is the Deputy Director General of IVI’s Government & Public Relations Unit. This unit oversees engagement with the Korean government and other global stakeholders. Dr. Han has more than 30 years’ experience as a senior official in the Korean government in the areas of economic policy and budgeting. Among his positions were: Director General of the Technology & Safety Policy Bureau, Ministry of Construction and Transportation; Director General of the Policy Analysis Bureau, National Economic Advisory Council; and Chief Executive Auditor of the Korea Credit Guarantee Fund. He was also an Adjunct Professor at Seoul National University of Science and Technology. Dr. Han has a Ph.D. in economics from the University of Hawaii; a Master of Science in management science from the Korea Advanced Institute of Science and Technology (KAIST); and a Master of Public Administration and a Bachelor of Arts in economics from Seoul National University. He is a Certified Internal Auditor of the Institute of Internal Auditors, U.S.A.

Dr. Manki Song is the Deputy Director General of IVI’s Science Unit. He has had a longstanding interest in public health and threats to health of developing country populations. In the first years of his career, he focused on viral diseases, particularly HIV, HBV and HCV. Most recently, as the Head of the Clinical Research Lab Department at IVI, he broadened the scope of his studies to include SARS-CoV-2, MERS-CoV, and SFTS vaccine development. Before joining IVI as a research scientist in 2004, Dr. Song served as an IVI postdoctoral fellow in 2001 at Prof. Myron Levine’s Center for Vaccine Development (CVD) at the University of Maryland School of Medicine in Baltimore, U.S.A. During this period, he focused on the development of new-generation measles vaccines using naked DNA, attenuated Shigella, and Salmonella. Dr. Song has also actively served on steering committees of many academic societies including the Korea Association of Immunologists and the Korean Vaccine Society. After two years of service as a Review Board member of the Korea National Research Foundation (Immunology in Medical Science), he has been working as a Program Manager of the state-run Korea Health Industry Development Institute (KHIDI) since 2015. Dr. Song received his B.Sc. degree from Seoul National University, and his M.Sc. and Ph.D. degrees from Pohang University of Science and Technology (POSTECH).